Published on December 22, 2009 at 3:46 AM
Urigen Pharmaceuticals, Inc. (OTCBB:URGP), a specialty pharmaceutical
company focused on the development of treatments for urological
disorders and pain, announced today that the Company and Oceana
Therapeutics have agreed to jointly prepare for a meeting with the U.S.
Food & Drug Administration regarding the continued development of URG101.
“Oceana has expertise in developing and commercializing drugs which are
delivered procedurally, including in urology”
"Oceana has expertise in developing and commercializing drugs which are
delivered procedurally, including in urology," said Urigen’s CEO William
J. Garner, MD. “This allows Urigen to move URG101 forward with a
talented potential partner to prepare for an FDA meeting.” David S.
Tierney, M.D., President and COO, Oceana Therapeutics, said, “We’re
excited about the potential of URG101, there is clearly an unmet medical
need in Painful Bladder Syndrome/Interstitial Cystitis.”
http://www.urigen.com/